Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

Phase 2

Terminated

Conditions: Chronic Graft-versus-host-disease

Interventions: Drug: Itacitinib

First Posted Date: 2019-12-16

Last Posted Date: 2024-11-06

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 15

Registration Number: NCT04200365

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
South Austin Medical Center, Austin, Texas, United States

and more 2 locations

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Solid Tumor

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Other: Chemotherapy (Arm A Only)

First Posted Date: 2019-06-06

Last Posted Date: 2024-08-12

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 46

Registration Number: NCT03977467

Locations: 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
🇺🇸
Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States

and more 4 locations

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Nivolumab

First Posted Date: 2018-02-19

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 37

Registration Number: NCT03436862

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
HCA Midwest, Kansas City, Missouri, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 3 locations

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase 2

Terminated

Conditions: Urothelial Carcinoma
Bladder Cancer
Transitional Cell Carcinoma

Interventions: Drug: nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2016-09-02

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 3

Registration Number: NCT02887248

Locations: 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States
🇺🇸
Florida Cancer Specialists-East, West Palm Beach, Florida, United States

and more 2 locations

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Phase 2

Terminated

Conditions: Carcinoid Tumors
Gastrointestinal Neoplasms
Neuroendocrine Tumors

Interventions: Drug: Lanreotide
Device: Y-90 microspheres

First Posted Date: 2016-08-08

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 6

Registration Number: NCT02859064

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Research Medical Center/HCA Midwest, Kansas City, Missouri, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone
Procedure: autologous stem cell transplantation

First Posted Date: 2016-07-25

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 53

Registration Number: NCT02843074

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States

and more 2 locations

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2

Completed

Conditions: Urothelial Carcinoma
Gastrointestinal Carcinoma, Non-colon
Upper Aerodigestive Tract Carcinoma
Non-small Cell Lung Carcinoma

Interventions: Drug: Afatinib
Drug: Regorafenib
Drug: Cabozantinib

First Posted Date: 2016-06-09

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 100

Registration Number: NCT02795156

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States

and more 5 locations

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Phase 1

Terminated

Conditions: Small Cell Lung Cancer
Ovarian Cancer

Interventions: Drug: LCL161
Drug: Topotecan
Drug: Pegylated GCSF (PEG-GCSF)

First Posted Date: 2016-01-07

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 34

Registration Number: NCT02649673

Locations: 🇺🇸
Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
🇺🇸
Oklahoma University Health Science Center/Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2015-05-07

Last Posted Date: 2020-09-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 74

Registration Number: NCT02436772

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

iCORE: Collaborative Orthopedics Outcomes Registry

Withdrawn

Conditions: Arthroplasty, Replacement, Hip
Arthroplasty, Replacement, Knee

First Posted Date: 2015-04-21

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02422667

Locations: 🇺🇸
SCRI, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy